Trial Profile

A Phase IIa Open-label Trial to Investigate the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Participants With Drug-sensitive Pulmonary Tuberculosis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2024 Results assessing early bactericidal activity , safety and pharmacokinetics published in the Nature Medicine
21 Oct 2023 Number of treatment arms have been increased from 2to 5 by the addition of 2 more experimental arms for different doses of GSK3036656.
24 Mar 2023 Results of the popPK model and validate the 2SB model based on data from the monotherapy EBA study (NCT03557281) in drug-sensitive TB patients , presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com